Proteomic diagnosis of Sjögren’s syndrome

References

• Ramos-Casals M, Tzioufas AG, Font J. Primary Sjögren’s syndrome: new clinical and therapeutic concepts. Ann. Rheum. Dis.64, 347–354 (2005).
   PubMed Web of Science ®Google Scholar
• Kassan SS, Moutsopoulos HM. Clinical manifestations and early diagnosis of Sjögren’s syndrome. Arch. Intern. Med.164, 1275–1284 (2004).
   PubMed Web of Science ®Google Scholar
• Youinou P, Daridon C, Saraux A, Devauchelle V, Pers JO. Is B-cell the conductor of the lymphocyte orchestra in the salivary glands of patients with primary Sjögren’s syndrome? Clin. Exp. Rheumatol.24, 491–492 (2006).
   Google Scholar
• Binard A, Devauchelle-Pensec V, Fautrel B, Jousse S, Youinou P, Saraux A. Epidemiology of Sjögren’s syndrome: where are we now? Clin. Exp. Rheumatol.25, 1–4 (2007).
   PubMed Web of Science ®Google Scholar
• Fox RI. Sjögren’s syndrome. Lancet366, 321–331 (2005).
   PubMed Web of Science ®Google Scholar
• Vitali C, Bombardieri S, Jonsson R et al. European Study Group on classification criteria for Sjögren’s syndrome. Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American–European Consensus Group. Ann. Rheum. Dis.61, 554–558 (2002).
   PubMed Web of Science ®Google Scholar
• Gran JT. Diagnosis and definition of primary Sjögren’s syndrome. Scand. J. Rheumatol.31, 57–59 (2002).
   PubMed Web of Science ®Google Scholar
• Hay EM, Thomas E, Pal B, Hajer A, Chambers H, Silman AJ. Weak association between subjective symptoms and objective testing for dry eyes and mouth: results from a population based study. Ann. Rheum. Dis.57, 20–24 (1998).
   PubMed Web of Science ®Google Scholar
• Manganelli P, Fietta P, Quaini F. Hematologic manifestations of primary Sjögren’s syndrome. Clin. Exp. Rheumatol.24, 438–448 (2006).
   PubMed Web of Science ®Google Scholar
• Voulgarelis M, Dafni UG, Isenberg DA, Moutsopoulos HM. Malignant lymphoma in primary Sjögren’s Syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjögren’s Syndrome. Arthritis Rheum.42, 1765–1772 (1999).
   PubMed Web of Science ®Google Scholar
• Hermansson M, Sawaji Y, Bolton M et al. Proteomic analysis of articular cartilage shows increased type II collagen synthesis in osteoarthritis and expression of inhibin βA (activin A), a regulatory molecule for chondrocytes. J. Biol. Chem.279, 43514–43521 (2004).
   PubMed Web of Science ®Google Scholar
• De Ceuninck F, Marcheteau E, Berger S et al. Assessment of some tools for the characterization of the human osteoarthritic cartilage proteome. J. Biomol. Tech.16, 256–265 (2005).
   PubMedGoogle Scholar
• Ruiz-Romero C, Lopez-Armada MJ, Blanco FJ. Proteomic characterization of human normal articular chondrocytes: a novel tool for the study of osteoarthritis and other rheumatic diseases. Proteomics5, 3048–3059 (2005).
   PubMed Web of Science ®Google Scholar
• Sinz A, Bantscheff M, Mikkat S et al. Mass spectrometric proteome analyses of synovial fluids and plasmas from patients suffering from rheumatoid arthritis and comparison to reactive arthritis or osteoarthritis. Electrophoresis23, 3445–3456 (2002).
   PubMed Web of Science ®Google Scholar
• Liao H, Wu J, Kuhn E et al. Use of mass spectrometry to identify protein biomarkers of disease severity in the synovial fluid and serum of patients with rheumatoid arthritis. Arthritis Rheum.50, 3792–3803 (2004).
   PubMed Web of Science ®Google Scholar
• Drynda S, Ringel B, Kekow M et al. Proteome analysis reveals disease-associated marker proteins to differentiate RA patients from other inflammatory joint diseases with the potential to monitor anti-TNFα therapy. Pathol. Res. Pract.200, 165–171 (2004).
   PubMed Web of Science ®Google Scholar
• de Seny D, Fillet M, Meuwis MA et al. Discovery of new rheumatoid arthritis biomarkers using the surface-enhanced laser desorption/ionization time-of-flight mass spectrometry ProteinChip approach. Arthritis Rheum.52, 3801–3812 (2005).
   PubMed Web of Science ®Google Scholar
• An Y, Pu H, He SZ, Li ZG. Identification of biomarkers in serum of early rheumatoid arthritis by proteomic methods. Zhonghua Yi Xue Za Zhi85, 1261–1265 (2005).
   Google Scholar
• Tilleman K, Van Beneden K, Dhondt A et al. Chronically inflamed synovium from spondyloarthropathy and rheumatoid arthritis investigated by protein expression profiling followed by tandem mass spectrometry. Proteomics5, 2247–2257 (2005).
   PubMed Web of Science ®Google Scholar
• Hueber W, Kidd BA, Tomooka BH et al. Antigen microarray profiling of autoantibodies in rheumatoid arthritis. Arthritis Rheum.52, 2645–2655 (2005).
   PubMed Web of Science ®Google Scholar
• Kim CW, Cho EH, Lee YJ, Kim YH, Hah YS, Kim DR. Disease-specific proteins from rheumatoid arthritis patients. J. Korean Med. Sci.21, 478–484 (2006).
   PubMed Web of Science ®Google Scholar
• Matsuo K, Xiang Y, Nakamura H et al. Identification of novel citrullinated autoantigens of synovium in rheumatoid arthritis using a proteomic approach. Arthritis Res. Ther.8, R175 (2006).
   PubMed Web of Science ®Google Scholar
• Hueber W, Tomooka BH, Zhao X et al. Proteomic analysis of secreted proteins in early rheumatoid arthritis: anti-citrulline autoreactivity is associated with up regulation of proinflammatory cytokines. Ann. Rheum. Dis.66, 712–719 (2007).
   PubMed Web of Science ®Google Scholar
• Roy SM, Becker CH. Quantification of proteins and metabolites by mass spectrometry without isotopic labeling. Methods Mol. Biol.359, 87–105 (2007).
   Google Scholar
• Stone JH, Rajapakse VN, Hoffman GS III et al. Wegener’s granulomatosis Etanercept Trial Research Group. A serum proteomic approach to gauging the state of remission in Wegener’s granulomatosis. Arthritis Rheum.52, 902–910 (2005).
   Google Scholar
• Fietta A, Bardoni A, Salvini R et al. Analysis of bronchoalveolar lavage fluid proteome from systemic sclerosis patients with or without functional, clinical and radiological signs of lung fibrosis. Arthritis Res. Ther.8, R160 (2006).
   PubMed Web of Science ®Google Scholar
• Giusti L, Bazzichi L, Baldini C et al. Specific proteins identified in human whole saliva from diffuse systemic sclerosis patients. J. Rheumatol. (2007) (In Press).
   Google Scholar
• Xiang Y, Matsui T, Matsuo K et al. Comprehensive investigation of disease-specific short peptides in sera from patients with systemic sclerosis: complement C3f-des-arginine, detected predominantly in systemic sclerosis sera, enhances proliferation of vascular endothelial cells. Arthritis Rheum.56, 2018–2030 (2007).
   PubMed Web of Science ®Google Scholar
• Häupl T, Krenn V, Stuhlmüller B, Radbruch A, Burmester GR. Perspectives and limitations of gene expression profiling in rheumatology: new molecular strategies. Arthritis Res. Ther.6, 140–146 (2004).
   Google Scholar
• Patterson SD. Proteomics: beginning to realise its promise?. Arthritis Rheum.50, 3741–3744 (2004).
   Google Scholar
• Ali M, Manolios N. Proteomics in rheumatology: a new direction for old diseases. Sem. Arthritis Rheum.35, 67–76 (2005).
   PubMed Web of Science ®Google Scholar
• Tilleman K, Deforce D, Elewaut D. Rheumatology: a close encounter with proteomics. Rheumatology44, 1217–1226 (2005).
   Google Scholar
• Wu T, Mohan C. Proteomics on the diagnostic horizon: lessons from rheumatology. Am. J. Med. Sci.333, 16–25 (2007).
   PubMed Web of Science ®Google Scholar
• O’Farrel PH. High resolution two-dimensional electrophoresis of proteins. J. Biol. Chem.250, 4007–4021 (1975).
   PubMed Web of Science ®Google Scholar
• Gorg A, Weiss W, Dunn MJ. Current two-dimensional electrophoresis technology for proteomics. Proteomics4, 3665–3685 (2004).
   PubMed Web of Science ®Google Scholar
• Delahunty C, Yates JR III. Protein identification using 2D-LC-MS/MS. Methods35, 248–255 (2005).
   PubMed Web of Science ®Google Scholar
• Aebersold R, Mann M. Mass spectrometry-based proteomics. Nature422, 198–207 (2003).
   PubMed Web of Science ®Google Scholar
• Fenn JB, Mann M, Meng CK, Wong SF, Whitehouse CM. Electrospray ionization for mass spectrometry of large biomolecules. Science246, 64–71 (1989).
   PubMed Web of Science ®Google Scholar
• Kislinger T, Emili A. Multidimensional protein identification technology: current status and future prospects. Expert Rev. Proteomics2, 27–39 (2005).
   PubMed Web of Science ®Google Scholar
• Seibert V, Wiesner A, Buschmann T, Meuer J. Surface-enhanced laser desorption ionization time-of-flight mass spectrometry (SELDI TOF-MS) and ProteinChip technology in proteomics research. Pathol. Res. Pract.200, 83–94 (2004).
   PubMed Web of Science ®Google Scholar
• Avisar R, Menaché R, Shaked P, Rubinstein J, Machtey I, Savir H. Lysozyme content of tears in patients with Sjögren’s syndrome and rheumatoid arthritis. Am. J. Ophthalmol.87, 148–151 (1979).
   PubMed Web of Science ®Google Scholar
• Janssen PT, van Bijsterveld OP. Tear fluid proteins in Sjögren’s syndrome. Scand. J. Rheumatol. Suppl.61(Suppl.), 224–227 (1986).
   PubMedGoogle Scholar
• Berta A, Török M. Tear glycoprotein determinations in the diagnosis and differential diagnosis of dry eyes. Scand. J. Rheumatol.61(Suppl.) 228–233 (1986).
   Google Scholar
• Suárez JC. Lacrymal proteins in Sjögren’s syndrome. Ophthalmologica194, 188–190 (1987).
   Google Scholar
• Boukes RJ, Boonstra A, Breebaart AC et al. Analysis of human tear protein profiles using high performance liquid chromatography (HPLC). Doc. Ophthalmol.67, 105–113 (1987).
   PubMed Web of Science ®Google Scholar
• van Bijsterveld OP, Mackor AJ. Sjögren’s syndrome and tear function parameters. Clin. Exp. Rheumatol.7, 151–154 (1989).
   Web of Science ®Google Scholar
• Markusse HM, Huysen JC, Nieuwenhuys EJ, Swaak AJ. β2 microglobulin in tear fluid from patients with primary Sjögren’s syndrome. Ann. Rheum. Dis.51, 503–505 (1992).
   PubMed Web of Science ®Google Scholar
• Markusse HM, van Haeringen NJ, Swaak AJ, Hogeweg M, de Jong PT. Tear fluid analysis in primary Sjögren’s syndrome. Clin. Exp. Rheumatol.11, 175–178 (1993).
   Google Scholar
• Ono M, Yoshino K, Tsubota K, Saito I. Subclass expression of IgA in lacrymal glands of patients with Sjögren’s syndrome Adv. Exp. Med. Biol.350, 185–188 (1994).
   Google Scholar
• Bjerrum KB. The ratio of albumin to lactoferrin in tear fluid as a diagnostic tool in primary Sjögren’s syndrome. Acta Ophthalmol. Scand.75, 507–511 (1997).
   PubMedGoogle Scholar
• Bjerrum KB. Tear fluid analysis in patients with primary Sjögren’s syndrome using lectin probes. A comparative study of patients with primary Sjögren’s syndrome, patients with other immune inflammatory connective tissue diseases and controls. Acta Ophthalmol. Scand.77, 1–8 (1999).
   Google Scholar
• Grus FH, Augustin AJ. Protein analysis methods in diagnosis of sicca syndrome. Ophthalmologe97, 54–61 (2000).
   Google Scholar
• Cojocaru VM, Ciurtin C, Puchianu E, Antohe F. Lacrimal proteins electrophoretic analysis – diagnostic method in secondary Sjögren’s syndrome. Oftalmologia50, 60–63 (2006).
   Google Scholar
• Talal N, Grey HM, Zvaifler N, Michalski JP, Daniels TE. Elevated salivary and synovial fluid β2-microglobulin in Sjögren’s syndrome and rheumatoid arthritis. Science187, 1196–1198 (1975).
   PubMedGoogle Scholar
• Michalski JP, Daniels TE, Talal N, Grey HM. β2 microglobulin and lymphocytic infiltration in Sjögren’s syndrome. N. Engl. J. Med.293, 1228–1231 (1975).
   PubMed Web of Science ®Google Scholar
• Mandel ID, Baurmash H. Sialochemistry in Sjögren’s syndrome. Oral Surg. Oral Med. Oral Pathol.41, 182–187 (1976).
   PubMedGoogle Scholar
• Tabak L, Mandel ID, Karlan D, Baurmash H. Alterations in lactoferrin in salivary gland disease. J. Dent. Res.57, 43–47 (1978).
   PubMed Web of Science ®Google Scholar
• Ghozlan R, Amor B, Mach PS, Delbarre F. Variations in salivary immunoglobulins in Sjögren’s syndrome. Rev. Stomatol. Chir. Maxillofac.79, 113–117 (1978).
   Google Scholar
• Moutsopoulos HM, Karsh J, Wolf RO, Tarpley TM, Tylenda A, Papadopoulos NM. Lysozyme determination in parotid saliva from patients with Sjögren’s syndrome. Am. J. Med.69, 39–42 (1980).
   Google Scholar
• Pennec Y, Ferrec C, Youinou P et al. Salivary lysozyme, immunoglobulins and β2-microglobulin in Gougerot-Sjögren syndrome. Nouv. Presse Med.11, 3481–3484 (1982).
   Google Scholar
• Stuchell RN, Mandel ID, Baurmash H. Clinical utilization of sialochemistry in Sjögren’s syndrome. J. Oral Pathol.13, 303–309 (1984).
   Google Scholar
• Tsianos EB, Tzioufas AG, Mavridis AK et al. Sialochemistry of patients with autoimmune rheumatic disease with and without histological manifestations of Sjögren’s syndrome. Ann. Rheum. Dis.44, 412–414 (1985).
   Google Scholar
• Fox PC, Sarras AK, Bowers MR, Drosos AA, Moutsopoulos HM. Oral and sialochemical findings in patients with autoimmune rheumatic disease. Clin. Exp. Rheumatol.5, 123–126 (1987).
   Google Scholar
• Friberg B, Jonsson R, Linde A. Salivary kallikrein in Sjögren’s syndrome. Clin. Exp. Rheumatol.6, 135–138 (1988).
   Google Scholar
• Jezequel N, Depasse F, Jouquan J et al. Salivary lactoferrin in primary Sjögren’s syndrome. Clin. Exp. Rheumatol.7, 123–125 (1989).
   Google Scholar
• Bianucci G, Campana G, Bongi SM, Palermo C, D’Agata A. Salivary and serum β2-microglobulin in the diagnosis of primary Sjögren’s syndrome. Minerva Med.83, 705–713 (1992).
   Google Scholar
• Markusse HM, Otten HG, Vroom TM, Smeets TJ, Fokkens N, Breedveld FC. The diagnostic value of salivary fluid levels of β2-microglobulin, lysozyme and lactoferrin for primary Sjögren’s syndrome. Clin. Rheumatol.11, 521–525 (1992).
   Google Scholar
• van der Geest SA, Markusse HM, Swaak AJ. β2 microglobulin measurements in saliva of patients with primary Sjögren’s syndrome: influence of flow. Ann. Rheum. Dis.52, 461–463 (1993).
   Google Scholar
• Mogi M, Kage T, Chino T, Yoshitake K, Harada M. Increased β2-microglobulin in both parotid and submandibular/sublingual saliva from patients with Sjögren’s syndrome. Arch. Oral Biol.39, 913–915 (1994).
   PubMedGoogle Scholar
• Maddali Bongi S, Campana G, D’Agata A, Palermo C, Bianucci G. The diagnosis value of β2-microglobulin and immunoglobulins in primary Sjögren’s syndrome. Clin. Rheumatol.14, 151–156 (1995).
   Google Scholar
• van der Reijden WA, van der Kwaak JS, Veerman EC, Nieuw Amerongen AV. Analysis of the concentration and output of whole salivary constituents in patients with Sjögren’s syndrome. Eur. J. Oral Sci.104, 335–340 (1996).
   PubMed Web of Science ®Google Scholar
• Carpenter GH, Proctor GB, Pankhurst CL, O’Donohue J, Scott D, Hunnable MP. Sialochemical markers of salivary gland involvement with Sjögren’s syndrome secondary to rheumatoid arthritis and primary biliary cirrhosis. J. Oral Pathol. Med.29, 452–459 (2000).
   PubMed Web of Science ®Google Scholar
• Almstähl A, Wikström M, Groenink J. Lactoferrin, amylase and mucin MUC5B and their relation to the oral microflora in hyposalivation of different origins. Oral Microbiol. Immunol.16, 345–352 (2001).
   PubMedGoogle Scholar
• Sistig S, Vucicevic-Boras V, Lukac J, Kusic Z. Salivary IgA and IgG subclasses in oral mucosal diseases. Oral Dis.8, 282–286 (2002).
   PubMed Web of Science ®Google Scholar
• Haghighat N, Al-Hashimi I. The status of lactoferrin and total iron binding capacity of human parotid saliva in Sjögren’s syndrome. Clin. Exp. Rheumatol.21, 485–488 (2003).
   Google Scholar
• Eliasson L, Almstähl A, Lingström P, Wikström M, Carlén A. Minor gland saliva flow rate and proteins in subjects with hyposalivation due to Sjögren’s syndrome and radiation therapy. Arch. Oral Biol.50, 293–299 (2005).
   Google Scholar
• Deming FP, Al-Hashimi I, Haghighat N et al. Comparison of salivary calmodulin binding proteins in Sjögren’s syndrome and healthy individuals. J. Oral Pathol. Med.36, 132–135 (2007).
   Google Scholar
• Beeley JA, Khoo KS. Salivary proteins in rheumatoid arthritis and Sjögren’s syndrome: one-dimensional and two-dimensional electrophoretic studies. Electrophoresis20, 1652–1660 (1999).
   PubMed Web of Science ®Google Scholar
• Tomosugi N, Kitagawa K, Takahashi N, Sugai S, Ishikawa I. Diagnostic potential of tear proteomic patterns in Sjögren’s syndrome J. Proteome Res.4, 820–825 (2005).
   PubMed Web of Science ®Google Scholar
• Ryu OH, Atkinson JC, Hoehn GT, Illei GG, Hart TC. Identification of parotid salivary biomarkers in Sjögren’s syndrome by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry and two-dimensional difference gel electrophoresis. Rheumatology45, 1077–1086 (2006).
   PubMed Web of Science ®Google Scholar
• Giusti L, Baldini C, Bazzichi L et al. Proteome analysis of whole saliva: a new tool for rheumatic diseases – the example of Sjögren’s syndrome. Proteomics7, 1634–1643 (2007).
   PubMed Web of Science ®Google Scholar
• Stea EA, Routsias JG, Samiotaki M et al. Analysis of parotid glands of primary Sjögren’s syndrome patients using proteomic technology reveals altered autoantigen composition and novel antigenic targets. Clin. Exp. Immunol.147, 81–89 (2007).
   PubMed Web of Science ®Google Scholar
• Peluso G, De Santis M, Inzitari C et al. Proteomic study of salivary peptides and proteins in patients with Sjögren’s syndrome before and after pilocarpine treatment. Arthritis Rheum.56, 2216–2222 (2007).
   PubMed Web of Science ®Google Scholar
• Amado FM, Vitorino RM, Domingues PM, Lobo MJ, Duarte JA. Analysis of the human saliva proteome. Expert Rev. Proteomics2, 521–539 (2005).
   PubMed Web of Science ®Google Scholar
• Horsfall AC, Rose LM, Maini RN. Autoantibody synthesis in salivary glands of Sjögren’s syndrome patients. J. Autoimmun.2, 559–566 (1989).
   PubMedGoogle Scholar
• Poon TC. Opportunities and limitations of SELDI-TOF-MS in biomedical research: practical advices. Expert Rev. Proteomics4, 51–65 (2007).
   PubMed Web of Science ®Google Scholar